Previous Close | 2.8500 |
Open | 2.8600 |
Bid | 2.7400 x 1000 |
Ask | 2.9800 x 800 |
Day's Range | 2.6950 - 3.1150 |
52 Week Range | 1.4800 - 8.7300 |
Volume | |
Avg. Volume | 1,009,376 |
Market Cap | 262.429M |
Beta (5Y Monthly) | 0.67 |
PE Ratio (TTM) | N/A |
EPS (TTM) | -1.5300 |
Earnings Date | Mar 04, 2024 - Mar 08, 2024 |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | 9.58 |
Subscribe to Yahoo Finance Plus to view Fair Value for ALLK
Financial Highlights and Business Updates from Allakos's Latest Earnings Filing
SAN CARLOS, Calif., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Allakos Inc. (the “Company”) (Nasdaq: ALLK), a biotechnology company developing antibodies for the treatment of allergic, inflammatory and proliferative diseases, today provided a business update and reported financial results for the third quarter ended September 30, 2023. Recent Allakos Events Completed enrollment in both the Phase 2 study of subcutaneous lirentelimab in patients with atopic dermatitis and the Phase 2b study of subcutaneous
Key Insights Given the large stake in the stock by institutions, Allakos' stock price might be vulnerable to their...